Katherine E Warren

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors
    Katherine E Warren
    National Cancer Institute Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Rd, Bethesda, MD 20892 8200, USA
    J Clin Oncol 23:7646-53. 2005
  2. ncbi request reprint Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group
    K Warren
    National Cancer Institute Neuro Oncology Branch, Bethesda, MD 20892 8200, USA
    Cancer Chemother Pharmacol 58:343-7. 2006
  3. pmc Diffuse intrinsic pontine glioma: poised for progress
    Katherine E Warren
    Pediatric Neuro Oncology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda, MD, USA
    Front Oncol 2:205. 2012
  4. doi request reprint Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group
    Katherine E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 60:1397-401. 2013
  5. pmc A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma
    Katherine Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer 118:3607-13. 2012
  6. pmc Genomic aberrations in pediatric diffuse intrinsic pontine gliomas
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Pediatric Neuro Oncology Section, Bldg 10 CRC, Rm 1W 5750, Bethesda, MD 20892 1104, USA
    Neuro Oncol 14:326-32. 2012
  7. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E Warren
    National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 62:433-7. 2008
  8. pmc A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study
    Katherine E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Neurooncol 106:643-9. 2012
  9. pmc Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Bldg 10 CRC, Rm 1 5750, Bethesda, MD 20892 1104, USA
    J Clin Oncol 29:324-9. 2011
  10. ncbi request reprint Noninvasive assessment of pediatric brain tumors
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD, USA
    Cancer Biol Ther 8:1881-8. 2009

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors
    Katherine E Warren
    National Cancer Institute Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Rd, Bethesda, MD 20892 8200, USA
    J Clin Oncol 23:7646-53. 2005
    ....
  2. ncbi request reprint Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group
    K Warren
    National Cancer Institute Neuro Oncology Branch, Bethesda, MD 20892 8200, USA
    Cancer Chemother Pharmacol 58:343-7. 2006
    ..The combination of lobradimil and carboplatin was studied in pediatric patients with primary brain tumors in a phase II trial, the primary endpoints of which were to estimate the response rate and time to disease progression...
  3. pmc Diffuse intrinsic pontine glioma: poised for progress
    Katherine E Warren
    Pediatric Neuro Oncology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda, MD, USA
    Front Oncol 2:205. 2012
    ..This review will summarize the current state of knowledge of DIPG, discuss obstacles to therapy, and summarize results of recent biologic studies...
  4. doi request reprint Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group
    Katherine E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 60:1397-401. 2013
    ..RAPNO was subsequently established to address unique issues in pediatric neuro-oncology. The aim of this paper is to delineate response criteria issues in pediatric clinical trials as a basis for subsequent recommendations...
  5. pmc A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma
    Katherine Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer 118:3607-13. 2012
    ..The primary objective was to compare 2-year survival with a historic cohort that received radiation therapy alone...
  6. pmc Genomic aberrations in pediatric diffuse intrinsic pontine gliomas
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Pediatric Neuro Oncology Section, Bldg 10 CRC, Rm 1W 5750, Bethesda, MD 20892 1104, USA
    Neuro Oncol 14:326-32. 2012
    ..This study establishes the feasibility of genomic DNA analysis from DIPG autopsy material, identifies several targets for which molecular targeted therapy exists, and suggests significant heterogeneity among patients with DIPG...
  7. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E Warren
    National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 62:433-7. 2008
    ..We studied the cerebrospinal fluid (CSF) penetration of intravenous (IV) belinostat in a non-human primate model as a surrogate for blood:brain barrier penetration...
  8. pmc A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study
    Katherine E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Neurooncol 106:643-9. 2012
    ..The combination of O6BG and TMZ did not achieve the target response rate for activity in pediatric patients with recurrent or progressive HGG and BSG...
  9. pmc Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Bldg 10 CRC, Rm 1 5750, Bethesda, MD 20892 1104, USA
    J Clin Oncol 29:324-9. 2011
    ..A phase I trial of lenalidomide was performed in children with recurrent, refractory, or progressive primary CNS tumors to estimate the maximum-tolerated dose (MTD) and to describe the toxicity profile and pharmacokinetics...
  10. ncbi request reprint Noninvasive assessment of pediatric brain tumors
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD, USA
    Cancer Biol Ther 8:1881-8. 2009
    ..This article reviews these techniques and their potential application to children with brain tumors...
  11. ncbi request reprint Molecularly targeted therapy for pediatric brain tumors
    Warren K E
    National Cancer Institute, Neuro Oncology Branch, Bloch Bldg, 82, Rm 224, 9030 Old Georgetown Road, Bethesda, Maryland 20892 8200, USA
    J Neurooncol 75:335-43. 2005
    ..This article discusses the rationale behind several of these agents and their use in pediatric patients with brain tumors...
  12. ncbi request reprint Current approaches to CNS tumors in infants and very young children
    Katherine E Warren
    Neuro Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Expert Rev Neurother 4:681-90. 2004
    ..Achieving successful tumor control while optimizing quality of life for survivors is the major goal of recent research...
  13. ncbi request reprint Advances in the assessment of childhood brain tumors and treatment-related sequelae
    Katherine E Warren
    National Cancer Institute, Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Road, Bethesda, MD 20892, USA
    Curr Neurol Neurosci Rep 5:119-26. 2005
    ..This article reviews some of these techniques and their role in the assessment of children with brain tumors...
  14. ncbi request reprint NMR spectroscopy and pediatric brain tumors
    Katherine E Warren
    Neuro Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 8200, USA
    Oncologist 9:312-8. 2004
    ..NMRS is commonly used in the evaluation of patients with brain tumors. This article reviews the basic principles of spectroscopy and its use in evaluating pediatric patients with brain tumors...
  15. ncbi request reprint Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors
    Katherine Warren
    Neuro Oncology Branch and Pediatric Oncology Branch, National Cancer Institute, Bloch Building, 82, 9030 Old Georgetown Road, Bethesda, MD 20892 8200, USA
    Cancer Chemother Pharmacol 54:206-12. 2004
    ..To determine the pharmacokinetics of adaptively dosed carboplatin when administered in combination with the bradykinin agonist, lobradimil (RMP-7, Cereport), to pediatric patients with brain tumors...
  16. ncbi request reprint Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors
    K E Warren
    Neuro Oncology Branch, National Cancer Institute NCI and National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892 1928, USA
    J Natl Cancer Inst 93:1401-5. 2001
    ..Because software to estimate three-dimensional (3D) tumor volume from digitized MRI images is available, we compared all three methods of tumor measurement for childhood brain tumors and clinical outcome...
  17. pmc Single- and multivoxel proton spectroscopy in pediatric patients with diffuse intrinsic pontine glioma
    Emilie A Steffen-Smith
    Pediatric Oncology Branch, National Cancer Institute, Building 10 Room 1 5750, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Int J Radiat Oncol Biol Phys 84:774-9. 2012
    ..Utility of each technique for improving patient management is also discussed...
  18. pmc Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma
    Emilie A Steffen-Smith
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Neurooncol 105:365-73. 2011
    ..This prospective study shows that MRS can be used to identify high-risk patients and monitor changes in tumor metabolism, which may reflect changes in tumor behavior...
  19. doi request reprint Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors
    Holly J Meany
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bldg 10 CRC Rm 1 5750, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:137-42. 2009
    ..Temozolomide pharmacokinetics were evaluated in children receiving concurrent O(6)-benzylguanine (O(6)BG), which enhanced the hematological toxicity of temozolomide...
  20. doi request reprint Measurements of the pons as a biomarker of progression for pediatric DIPG
    Emilie A Steffen-Smith
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10 Room 1 5750, 9000 Rockville Pike, Bethesda, MD, 20892, USA
    J Neurooncol 116:127-33. 2014
    ..Measurements of the pons (as opposed to direct measurements of tumor) are a viable in vivo biomarker for DIPG...
  21. doi request reprint The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates
    Leigh Marcus
    National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Building 10 CRC, Room 1 5742, Bethesda, MD 20892 1101, USA
    Cancer Chemother Pharmacol 69:247-52. 2012
    ..7 and 2.6%, respectively). We evaluated the plasma and CSF pharmacokinetics (PK) of satraplatin after an intravenous (IV) dose in NHP...
  22. pmc Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging
    Sean J Hipp
    Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Neuro Oncol 13:904-9. 2011
    ..Routine baseline and subsequent imaging for children with DIPG should, at minimum, incorporate DSC-MRI and SVS...
  23. pmc Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta)
    Cynthia M McCully
    National Cancer Institute, Bethesda, Maryland, USA
    Comp Med 63:355-60. 2013
    ..This animal model allows for the determination of differences in CNS penetration of chemotherapeutic agents in the pons, cortex, and CSF after systemic drug administration. ..
  24. doi request reprint Role of early postradiation magnetic resonance imaging scans in children with diffuse intrinsic pontine glioma
    Christine Ko
    Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Int J Radiat Oncol Biol Phys 83:1252-6. 2012
    ..To determine optimal timing of assessing postradiation radiographic response on magnetic resonance imaging (MRI) scans in pediatric patients with diffuse intrinsic pontine glioma (DIPG)...
  25. doi request reprint Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates
    Nirali N Shah
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1W 3750, 9000, Rockville Pike, Bethesda, MD, 20892 1104, USA
    Invest New Drugs 34:61-5. 2016
    ..We report our results comparing CSF and plasma pharmacokinetic parameters of intravenous aqueous vincristine to intravenous VSLI using an established non-human primate (NHP) model...
  26. pmc Development of a cerebrospinal fluid lateral reservoir model in rhesus monkeys (Macaca mulatta)
    Cynthia M Lester McCully
    National Cancer Institute, Bethesda Maryland, USA
    Comp Med 65:77-82. 2015
    ..Development of the LR model was successful in rhesus macaques and is a useful alternative to the FR and LP methods of CSF collection from nonhuman primates. ..
  27. pmc Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy
    Emilie A Steffen-Smith
    Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Childs Nerv Syst 24:807-13. 2008
    ....
  28. pmc Molecular imaging of pediatric brain tumors: comparison of tumor metabolism using ¹⁸F-FDG-PET and MRSI
    Sean J Hipp
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Neurooncol 109:521-7. 2012
    ..1-47.5 %). These results indicate that FDG-PET and MRSI detect similar but not always identical regions of tumor activity, and there is little agreement in the degree of tumor metabolic activity between the two techniques...
  29. ncbi request reprint Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 18:1020-6. 2000
    ..We measured the relative tumor concentrations of these biochemical markers in children with recurrent brain tumors and evaluated their potential prognostic significance...
  30. ncbi request reprint Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1928, USA
    Cancer Chemother Pharmacol 48:275-82. 2001
    ..To determine the maximum tolerated dose (MTD), the incidence and severity of toxicities, and the pharmacokinetics of lobradimil administered intravenously over 10 min in combination with carboplatin in children with refractory brain tumors...
  31. pmc Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1928, USA
    Antimicrob Agents Chemother 44:1100-1. 2000
    ..Fluconazole pretreatment had no effect on doxorubicin pharmacokinetics...
  32. ncbi request reprint Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates
    K E Warren
    Pediatric Oncology Branch, Bldg 10 Rm 13N240, 10 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 45:207-12. 2000
    ..We studied the effects of the Pgp inhibitor, cyclosporin A (CsA), on the cerebrospinal fluid (CSF) penetration of the Pgp substrate, doxorubicin, in non-human primates...
  33. pmc Minimally Invasive Lumbar Port System for the Collection of Cerebrospinal Fluid from Rhesus Macaques (Macaca mulatta)
    Rhonda Pung MacAllister
    National Cancer Institute, Bethesda, Maryland, USA Oregon National Primate Research Center, Beaverton, Oregon, USA
    Comp Med 66:349-52. 2016
    ..The MILP system is an appropriate replacement for temporary catheterization and previous models requiring laminectomy and is a short-term alternative for ventricular CSF collection systems in NHP. ..
  34. pmc Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition
    Isabella C Taylor
    From the Division of Neuropathology and Sidney Kimmel Comprehensive Cancer Center ICT, MH C, WB, CGE, EHR and Division of Pediatric Oncology ICT, EHR, Johns Hopkins University, Bloomberg Children s Hospital, Baltimore, Maryland Children s National Medical Center and George Washington University School of Medicine and Health Sciences, Washington, District of Columbia MK, JN Department of Neurology and Ophthalmology, Michigan State University, East Lansing HTC and Sparrow Health System, Lansing HTC, Michigan and Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland KEW
    J Neuropathol Exp Neurol 74:778-90. 2015
    ....
  35. pmc Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas
    Robert M Hayward
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10 CRC, Rm 1 3940, Bethesda, MD 20892, USA
    J Neurooncol 90:57-61. 2008
    ..Endpoints for clinical trials determining efficacy in this population should also include more objective measures, such as survival, and additional endpoints need to be investigated...
  36. pmc Diffusion tensor histogram analysis of pediatric diffuse intrinsic pontine glioma
    Emilie A Steffen-Smith
    Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Building 10, Room 1 5750, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Biomed Res Int 2014:647356. 2014
    ....
  37. doi request reprint Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model
    Diane E Cole
    Pharmacology and Experimental Therapeutics, POB, NCI, NIH, Bethesda, MD, 20892, USA
    Cancer Chemother Pharmacol 75:923-8. 2015
    ..We evaluated the plasma and cerebrospinal fluid pharmacokinetics of orally administered perifosine in a non-human primate model to evaluate CNS penetration...
  38. pmc Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors
    Srivandana Akshintala
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Pediatr Blood Cancer 62:603-10. 2015
    ....
  39. ncbi request reprint Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note
    Russell R Lonser
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 1414, USA
    J Neurosurg 107:190-7. 2007
    ..Patients with a variety of intrinsic brainstem and other central nervous system disorders may benefit from a similar treatment paradigm...
  40. pmc Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma
    Sama Ahsan
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 1800 Orleans St, 21287 Baltimore, MD, USA
    Acta Neuropathol Commun 2:59. 2014
    ..An H-score was derived by multiplying intensity (0-2) by percentage of positive tumor nuclei (0-100%)...